13D Filing: Muneer A Satter and Vital Therapies Inc (NASDAQ:VTL)

---

SCHEDULE 13D

CUSIP No. 92847R104		Page 4 of 8

The Reporting Person has no current intention to propose changes in the Companys
operations, governance or capitalization, or to propose one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Person reserves the right to formulate other plans
and/or make other proposals, and take such actions with respect to his investment in the Company, including any or all of the actions set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D, or to acquire additional shares
of Common Stock or dispose of all the Common Stock beneficially owned by him, in the public market, in privately negotiated transactions (which may be with the Company or with third parties) or otherwise. The Reporting Person may at any time
reconsider and change his plans or proposals relating to the foregoing.

Item 5. Interest in Securities of the Issuer.

(a)

Amount beneficially owned as of the date hereof:

The Reporting Person beneficially owns
an aggregate of 11,034,688 shares of Common Stock. The shares of Common Stock beneficially owned by the Reporting Person include (a) 4,202,930 shares of Common Stock that are held by Muneer A. Satter Revocable Trust for which the Reporting
Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares; (b) 2,929,347 shares of Common Stock that are held by various other trusts and other entities for which the Reporting Person serves as
trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares; (c) 3,750,000 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole
voting and dispositive power over all such shares; (d) warrants to acquire 60,639 shares of Common Stock that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has the sole
power to exercise such warrants and sole voting and dispositive power over all shares underlying such warrants; (e) warrants to acquire 61,533 shares of Common Stock that are held by various trusts and other entities for which the Reporting
Person serves as trustee, investment advisor or manager, and in such capacity, has the sole power to exercise such warrants and sole voting and dispositive power over all shares underlying such warrants; and (f) stock options to purchase 30,239
shares of Common Stock, which vest on the earlier of May 24, 2017 and the date immediately prior to the Issuers 2017 annual meeting of stockholders.

Percent

of class:

In the aggregate, the Reporting Persons beneficially own 11,034,688 shares of
Common Stock, or 26.9% of the total number of shares of Common Stock outstanding.

All percentages calculated in this Schedule 13D are
based upon 40,893,475 shares outstanding (which assumes no exercise of the underwriters option to purchase additional shares) as of March 22, 2017, as disclosed in the Companys Prospectus Supplement filed with the Securities and
Exchange Commission (SEC) on March 23, 2017.

(b)

Number of shares as to which such person has:

(i)

sole power to vote or to direct the vote: See Item 7 on the cover pages hereto.

(ii)

shared power to vote or to direct the vote: See Item 8 on the cover pages hereto.

(iii)

sole power to dispose or to direct the disposition of: See Item 9 on the cover pages hereto.

(iv)

shared power to dispose or to direct the disposition of: See Item 10 on the cover pages hereto.

(c)

The information set forth in Item 3 of this Schedule 13D is hereby incorporated by reference into this Item 5(c), as applicable.

(d)

Not applicable

(e)

Not applicable